ZA95628B - Preparation of recombinant adeno-associated viruses (aavs) and their use - Google Patents

Preparation of recombinant adeno-associated viruses (aavs) and their use

Info

Publication number
ZA95628B
ZA95628B ZA95628A ZA95628A ZA95628B ZA 95628 B ZA95628 B ZA 95628B ZA 95628 A ZA95628 A ZA 95628A ZA 95628 A ZA95628 A ZA 95628A ZA 95628 B ZA95628 B ZA 95628B
Authority
ZA
South Africa
Prior art keywords
pct
associated viruses
aavs
preparation
recombinant adeno
Prior art date
Application number
ZA95628A
Other languages
English (en)
Inventor
Vincent Descamps
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA95628B publication Critical patent/ZA95628B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA95628A 1994-01-28 1995-01-26 Preparation of recombinant adeno-associated viruses (aavs) and their use ZA95628B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9400934A FR2716682B1 (fr) 1994-01-28 1994-01-28 Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.

Publications (1)

Publication Number Publication Date
ZA95628B true ZA95628B (en) 1995-10-23

Family

ID=9459501

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95628A ZA95628B (en) 1994-01-28 1995-01-26 Preparation of recombinant adeno-associated viruses (aavs) and their use

Country Status (17)

Country Link
US (1) US5789390A (de)
EP (1) EP0741793B1 (de)
JP (1) JP3810078B2 (de)
KR (1) KR100403708B1 (de)
AT (1) ATE310097T1 (de)
AU (1) AU706647B2 (de)
CA (1) CA2181602A1 (de)
DE (1) DE69534618T2 (de)
DK (1) DK0741793T3 (de)
ES (1) ES2252738T3 (de)
FI (1) FI962990A7 (de)
FR (1) FR2716682B1 (de)
IL (1) IL112461A0 (de)
MX (1) MX9603002A (de)
NO (1) NO319885B1 (de)
WO (1) WO1995020671A1 (de)
ZA (1) ZA95628B (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2738575B1 (fr) * 1995-09-08 1997-10-10 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US6207457B1 (en) * 1995-09-08 2001-03-27 Avigen, Inc. Targeted nucleotide sequence delivery and integration system
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
US20020037867A1 (en) * 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
EP0928202A4 (de) * 1996-09-25 2001-09-05 Cell Genesys Inc Nicht-invasive verabreichung von adeno-assoziierten viralen vektoren
JP2001506133A (ja) * 1996-12-18 2001-05-15 ターゲティッド ジェネティクス コーポレイション 組換えａａｖベクターの産生における使用のための、ａａｖスプリット−パッケージング遺伝子およびこのような遺伝子を含む細胞株
US20040161409A1 (en) * 1997-07-25 2004-08-19 Kurtzman Gary J. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
WO1999028346A1 (de) * 1997-12-03 1999-06-10 Roche Diagnostics Gmbh Erythropoietin mit hoher spezifischer aktivität
DE19830141A1 (de) * 1998-07-06 2000-01-13 Regine Heilbronn Rekombinante Herpesviren für die Erzeugung rekombinanter Adeno-Assoziierter-Viren
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
US6759050B1 (en) * 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
DE19905501B4 (de) * 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20040043488A1 (en) * 1999-02-17 2004-03-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Adeno-associated viral gene-transfer vector system
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US7208315B2 (en) 2000-01-05 2007-04-24 Fred Hutchinson Cancer Research Center Compositions and methods for efficient AAV vector production
AU2001239884B2 (en) * 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
IL155154A0 (en) * 2000-09-30 2003-10-31 Diversa Corp Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US6916635B2 (en) * 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
WO2003025161A1 (en) 2001-09-18 2003-03-27 Clontech Laboratories, Inc. Site-specific recombinase based method for producing adenoviral vectors
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
EP1579004B1 (de) * 2002-10-23 2010-06-16 VIRxSYS Corporation Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
EP1670415A4 (de) * 2003-09-12 2007-12-05 Vertex Pharma Tiermodell für die proteaseaktivität und leberschäden
EP1716165A4 (de) * 2004-01-23 2008-06-18 Virxsys Corp Expression von apoa-1 und varianten davon unter verwendung des spleissosom-vermittelten rna-trans-spleissens
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
EP1732947B1 (de) 2004-03-05 2011-04-27 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7582442B2 (en) 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
EP1755400A2 (de) * 2004-06-18 2007-02-28 The University Of Montana Aav-vermittelte genabgabe an kochlearzellen
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
FI20050753A7 (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
EP1831365B1 (de) * 2004-10-08 2013-08-07 VIRxSYS Corporation Verwendung von rns trans-splicing zum antikörper gen transfer und zur antikörperherstellung
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
US7531523B2 (en) * 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
CN101163494A (zh) * 2005-02-23 2008-04-16 Uab研究基金会 烷基糖苷增强的接种
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
EP1919944B1 (de) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
WO2007089780A2 (en) * 2006-01-30 2007-08-09 Licentia, Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
PL2018184T3 (pl) 2006-05-17 2013-12-31 The Ludwig Institute For Cancer Res Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JP2011526916A (ja) * 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 全身性紅斑性狼瘡を同定および処置するための診断標的および治療標的としてのリソソームホスホリパーゼａ２（ｌｐｌａ２）活性
AU2012255143A1 (en) 2011-05-19 2014-02-20 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
PT2785683T (pt) 2011-11-30 2020-04-16 Ludwig Inst For Cancer Res Ltd Moduladores de célula inkt e métodos para o seu uso
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
HUE054260T2 (hu) 2012-09-06 2021-08-30 Univ Chicago Antiszensz polinukleotidok exon-ugrás indukálására és eljárások disztrófiák kezelésére
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
PT3283500T (pt) 2015-04-08 2021-01-28 Univ Chicago Composições e métodos para corrigir distrofia muscular das cinturas tipo 2c com utilização de salto do exão
MX2020013450A (es) 2018-06-11 2021-08-11 Univ Florida Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés.
EP4704807A1 (de) 2023-05-03 2026-03-11 IOX Therapeutics Limited Liposomale inkt-zellmodulatorzusammensetzungen und verfahren zur verwendung
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors

Also Published As

Publication number Publication date
JP3810078B2 (ja) 2006-08-16
NO962950D0 (no) 1996-07-12
FR2716682A1 (fr) 1995-09-01
KR100403708B1 (ko) 2004-05-31
ATE310097T1 (de) 2005-12-15
JPH09509051A (ja) 1997-09-16
DE69534618D1 (de) 2005-12-22
EP0741793B1 (de) 2005-11-16
FI962990L (fi) 1996-07-26
IL112461A0 (en) 1995-03-30
DE69534618T2 (de) 2006-07-27
AU1539595A (en) 1995-08-15
AU706647B2 (en) 1999-06-17
DK0741793T3 (da) 2006-03-27
US5789390A (en) 1998-08-04
FI962990A0 (fi) 1996-07-26
FR2716682B1 (fr) 1996-04-26
WO1995020671A1 (fr) 1995-08-03
FI962990A7 (fi) 1996-07-26
MX9603002A (es) 1997-06-28
EP0741793A1 (de) 1996-11-13
NO319885B1 (no) 2005-09-26
CA2181602A1 (fr) 1995-08-03
ES2252738T3 (es) 2006-05-16
NO962950L (no) 1996-07-12

Similar Documents

Publication Publication Date Title
IL112461A0 (en) Preparation of recombinant adeno-associated viruses (aavs) and their use
ATE362542T1 (de) Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
DE69739860D1 (de) Rekombinante AAV zur Herstellung eines Medikaments für die Gentherapie von Muskelzellen
CA2187626A1 (en) Aav-mediated delivery of dna to cells of the nervous system
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
PT1000146E (pt) Ests 5' para proteinas secretadas sem especificidade tecidular
PL331005A1 (en) Regulating dna of hamster's ef-1alpha transcription
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
DK1783225T3 (da) Strukturprotein fra AAV, dets fremstilling og anvendelse
DE69635931D1 (de) Komplementäre adenovirenvektorsysteme und zellinien
WO1997032991A3 (en) Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
GR3035050T3 (en) Method of preparing a viral vector by homologous intermolecular recombination
WO1998028317A3 (en) Synthesis of nucleosides and polynucleotides
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
CA2199832A1 (en) Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
AU5318496A (en) Adenovirus vectors for gene therapy
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
IL115432A0 (en) Viral vectors and their uses in gene therapy
PL320481A1 (en) Composition for treating creatine substances, containing at least one grafted silicone polymer of polysiloxane skeleton grafted with organic non-silicone monomers and at least one anionic polymer
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
EP1845163A3 (de) Adeno-assoziierte Virus-Serotyp-I-Nukleinsäuresequenzen und diese enthaltende Vektoren und Wirtszellen
EP0770137A4 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
HU9601298D0 (en) Endothelin-converting enzyme